October 10, 2025Open Access

Are Intravenous Immunoglobulins Effective in Preventing Primary EBV Infection in Pediatric Kidney Transplant Recipients?

View Full Paper

Ask AI

Bookmark

IVIG treatment was linked to a higher incidence of EBV infection (64% vs. 25%), contradicting its intended preventive effects.
Cumulative incidence was analyzed with a hazard ratio of 3.24, suggesting increased risk in the IVIG group, though not statistically significant.
Retrospective analysis involved 26 pediatric kidney transplant recipients with a follow-up of 7.5 years, examining IVIG's role in EBV prevention.
Findings suggest IVIG may not only fail to protect against EBV but could also increase susceptibility to the virus in high-risk patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Case-control study shows IVIG treatment increased EBV infection risk in pediatric kidney transplant recipients, indicating it may not be effective.

Partigiani et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Case-control study shows IVIG treatment increased EBV infection risk in pediatric kidney transplant recipients, indicating it may not be effective.